Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic threat. According to Sanofi, the 58,000 sq m facility can produce up to four vaccines or biologic treatments at one time, and swap one product for another within a week – something that could take months with a conventional plant design. Source: PharmaPhorum 29/11/2024